Your browser is no longer supported. Please, upgrade your browser.
MRK Merck & Co., Inc. daily Stock Chart
Merck & Co., Inc.
IndexDJIA S&P500 P/E31.71 EPS (ttm)1.97 Insider Own0.04% Shs Outstand2.77B Perf Week3.43%
Market Cap172.37B Forward P/E16.12 EPS next Y3.87 Insider Trans-39.61% Shs Float2.75B Perf Month0.89%
Income5.49B PEG4.80 EPS next Q0.89 Inst Own74.50% Short Float0.63% Perf Quarter0.49%
Sales39.91B P/S4.32 EPS this Y-61.60% Inst Trans-0.01% Short Ratio1.55 Perf Half Y6.12%
Book/sh15.82 P/B3.94 EPS next Y2.17% ROA5.60% Target Price- Perf Year24.23%
Cash/sh4.76 P/C13.10 EPS next 5Y6.60% ROE12.50% 52W Range46.47 - 64.96 Perf YTD5.89%
Dividend1.88 P/FCF256.89 EPS past 5Y41.50% ROI6.40% 52W High-4.04% Beta0.79
Dividend %3.02% Quick Ratio1.60 Sales past 5Y-3.00% Gross Margin64.50% 52W Low34.15% ATR1.16
Employees68000 Current Ratio1.90 Sales Q/Q4.60% Oper. Margin19.60% RSI (14)59.93 Volatility2.26% 1.68%
OptionableYes Debt/Eq0.57 EPS Q/Q21.80% Profit Margin13.80% Rel Volume0.88 Prev Close62.21
ShortableYes LT Debt/Eq0.54 EarningsFeb 02 BMO Payout92.90% Avg Volume11.18M Price62.34
Recom- SMA203.10% SMA502.55% SMA2006.18% Volume9,943,400 Change0.21%
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Dec-19-16Downgrade Jefferies Hold → Underperform
Oct-13-16Upgrade BofA/Merrill Neutral → Buy
Sep-09-16Reiterated Barclays Overweight $66 → $72
Aug-08-16Upgrade Credit Suisse Neutral → Outperform $73
Aug-08-16Reiterated Deutsche Bank Hold $58 → $59
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-16-17 10:14AM  These 5 Drug Patents Will Expire in 2017 at Investopedia
07:37AM  How Does Novartiss Valuation Compare to Peers?
Jan-14-17 10:15AM  Merck Is Best Performing DJIA Stock So Far in 2017
Jan-13-17 12:52PM  Merck Carries Incyte On Keytruda Coattails In 4 'Hot' Tumors: Leerink
11:01AM  [$$] Drug Pricing May Linger Over Biotech in 2017 at
09:30AM  Latest Reports on Stocks to Watch: AK Steel and Merck Accesswire
08:23AM  Coverage initiated on Merck by Bryan Garnier
Jan-12-17 04:07PM  Nasdaq Suffers First 2017 Loss, But Stocks Well Off Lows
03:44PM  Merck Is a 'Risk Worth Taking' in Spite of Trump Comments, Top Trader Claims
03:22PM  Investors in big pharma, biotech look to ride out Trump storm
02:40PM  Stocks Pare Losses; Apple, Disney Weigh On Dow; Can Nvidia Halt Slide?
02:25PM  Germanys Merck Taps Palantir for Big Data Health Initiative at Bloomberg
02:00PM  Eli Lilly Rebounds On Chemo-Drug Patent Win Vs. Generic Teva
01:20PM  Why 3 Analysts Upgraded Merck Simultaneously
12:43PM  2 Upgrades In 1 Day for Merck -- and 3 Things You Need to Know at Motley Fool
11:14AM  Bristol-Myers Threatens Merck's 'Head Start' In Lung Cancer: Analyst
10:50AM  Major Pharma Short Interest Declines Ahead of Trump Comments
10:12AM  Markets Sound The Retreat In Early Trading; Merck 'New Best Idea'
10:10AM  Company News for January 12, 2017
10:08AM  Jim Cramer -- We Can't Stifle Innovation in Health Care
09:56AM  Why You Should Watch These 6 Stocks Rising on Unusual Volume
09:55AM  3 Charts Every Bristol-Myers Squibb Shareholder Needs to See at Motley Fool
09:54AM  Merck: News So Good Three Analysts Had to Upgrade It at
09:39AM  Stocks Open Lower; Dollar Slides As Market Awaits Fed Comments
09:13AM  Top Analyst Upgrades and Downgrades: AK Steel, Merck, Twitter, US Steel, Disney, Xerox and More
08:43AM  Merck KGaA, Vertex Announce Tie-Up for Oncology Programs
08:11AM  Analysts' Actions -- Bank of America, Merck, Morgan Stanley, Valero and More
07:48AM  Lilly, Merck Expand Tie-Up to Study Lartruvo-Keytruda Combo
07:35AM  Trump criticism leads to falling stock prices at these Tampa employers at
01:40AM  Health-Care Stocks Tumble but Indexes Rise at The Wall Street Journal
Jan-11-17 07:01PM  Cramer: What Happened to the Pajama Traders?
07:00PM  Cramer gets to the bottom of the mysterious disappearance of pajama traders since Election Day at CNBC
06:15PM  Cramer's 2 sweet-spot plays on Trump's hatred of the pharmaceutical industry at CNBC
05:05PM  Mylans EpiPen Controversy: Is It a Brand or a Generic?
04:53PM  Merck and United jump while Signet and SuperValu fall
04:16PM  Nasdaq Posts Another Record Close in Unpredictable Trump-Triggered Trading Session
04:06PM  Nasdaq closes at fifth straight record as stocks finish higher at MarketWatch
04:01PM  Merck, IBM Pace DJIA to Wednesday Gain
03:22PM  Wednesdays Top Biopharma Movers
03:16PM  Stocks Back to Gains in Unsettled Trade After Trump News Conference
03:00PM  Trump Talks; Biotechs, Lockheed Fall; Merck Buoys Dow, Microchip Up
01:41PM  Trump Shoots Down Biotechs, Lockheed; Apple, Nvidia Weigh On Nasdaq
12:46PM  Dow In Driver's Seat As Merck Up; Middleby, SodaStream, Barracuda Pop
12:28PM  Merck Lung-Cancer Drug May Get OK For Large Patient Population
12:09PM  For Merck, Keytruda Is 'Extraordinarily Positive' : More Squawk From Jim Cramer
11:51AM  Why Rite Aid, Ford, Merck Are Wednesday's Most Active Movers
11:35AM  Vertex deals cancer drug programs to Merck KGaA for $230M at
10:49AM  Dow Makes Another Run at 20000 at The Wall Street Journal
10:29AM  Merck: One Giant Leap at
10:18AM  Markets Calm Ahead Of Trump Press Conference; HealthEquity In Buy Zone
10:10AM  Merck boosts Dow, Amazon prime members get a new perk, ADM to buy pet food producer
09:52AM  Merck leapfrogs rivals in lung cancer drug combination race Reuters
09:45AM  Stocks in holding pattern ahead of Trump news conference at MarketWatch
09:08AM  Morning Movers: Citigroup Slips on Cut; United Continental Flies at
08:27AM  Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults
08:18AM  Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer
08:12AM  Investors bide their time as Trump prepares to talkafter more tweets
Jan-10-17 07:15PM  Trump Tax Policies Could Make J&J a Bigger Threat in 2017
06:17PM  Kite Pharma Inks Deals for CAR T Cell Drug in Japan, China
06:11PM  FDA accepts Merck application for lung cancer combo therapy
05:04PM  US Market Indexes Trade Flat
05:01PM  Merck shares rise after hours on priority review lung cancer drug application at MarketWatch
04:55PM  Nasdaq closes at 4th straight recordmarks best such streak since 1999 at MarketWatch
04:06PM  Merck Receives FDA Acceptance of Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer Business Wire
01:46PM  Merck KGaA CEO: Drug Pricing Debate Is Natural
01:46PM  Merck KGaA CEO: Drug Pricing Debate Is Natural at Bloomberg
11:40AM  Incyte's Prospects Get Even Brighter With Merck Announcement at Motley Fool
10:07AM  Merck CEO: Seeing revolutionary change in the cure for cancer
10:05AM  Merck CEO on reforming Obamacare
09:12AM  Roche Gets Priority Review for Immunotherapy Drug Tecentriq
08:58AM  Incyte/Merck to Start More Epacadostat-Keytruda Studies
08:24AM  3 'Dogs of the Dow' Paying Up To 4.3% at Forbes
08:23AM  Here's a Biotech IPO You'll Want to Watch at Motley Fool
07:26AM  Merck & Co., Inc. breached its 50 day moving average in a Bullish Manner : MRK-US : January 10, 2017
05:40AM  Cambridges most secretive biotech, Moderna, gives a rare glimpse of its projects at
Jan-09-17 07:01PM  Cramer: A Dozen Stocks in the Dow That Can Regain Their Former Glory
06:24PM  There are illnesses that could bankrupt our society, Merck CEO says at CNBC
05:00PM  Apple helps Nasdaq to record high; Dow down, J.C. Penney, Sears, Macys slide at
04:24PM  Merck CEO: Illnesses could bankrupt society
02:59PM  Stocks Still Mixed, Medicals Lead Upside; Is Incyte The Next Amgen?
02:19PM  Piper Bullish On Pfizer and Eli Lilly at Investopedia
01:57PM  Merck Cancer Drug Test Sends Incyte Shares Higher
12:14PM  Incyte Stock Breaks Out, It And Partner Merck Will Advance Key Trial
11:40AM  Exclusive: Ziopharm CEO Talks Partnerships, Balance Sheet And JPM Healthcare Conference Presentation
09:59AM  Biotech Stocks Surge Monday Amid Flurry of Deal Activity
08:50AM  Dogs of the Dow Could Be a Huge Winner Again in 2017
08:00AM  Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab) Business Wire
Jan-08-17 02:00PM  3 Takeover Candidates in the Drug Space
Jan-06-17 11:01AM  It Was CheckMate for Bristol-Myers Squibb Company in 2016 at Motley Fool
10:28AM  Could Amgen's Patent Victory Be Bad For Medicine? at Forbes
09:42AM  2 Big Reasons Merck & Co., Inc. Stock Surged 11% in 2016 at Motley Fool
08:24AM  The Best Thing About Glaxo's Next Vaccine (Hint: It's Not the Billion-Dollar Sales Estimate) at Motley Fool
08:19AM  Halozyme (HALO) Up on Positive Phase II Data on PEGPH20
08:00AM  Merck to Participate at the 35th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-05-17 02:50PM  Merck, Moffitts M2Gen join forces in cancer research network at
02:50PM  Here's who won big in last year's top 10 VC-backed startup sales in the Bay Area at
11:05AM  2017 Bull-Bear Case for Health Care: J&J, Merck, Pfizer, UnitedHealth
08:10AM  How a Slimmer Procter & Gamble Might Fare in 2017
08:06AM  Lilly Jardiance Family Diabetes Drugs' Label to be Updated
12:01AM  [$$] Eli Lilly's new chief seeks to recover from Alzheimer's drug flop at Financial Times
Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise23.45133,9203,140,424642,797Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale65.03133,9208,709,286508,877Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Option Exercise23.456,080142,576514,957Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Sale65.006,080395,200508,877Nov 10 05:29 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise41.5385,5233,551,946124,638Nov 08 11:51 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale60.0285,5235,133,33039,115Nov 08 11:51 AM
LAZARUS ROCHELLE BDirectorNov 02Option Exercise37.3520,000746,95024,594Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Option Exercise51.865,000259,3006,000Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Sale59.505,000297,5001,000Nov 02 04:54 PM
LAZARUS ROCHELLE BDirectorNov 02Sale59.0620,0001,181,2004,594Nov 02 04:54 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Option Exercise44.1940,8001,802,952128,973Oct 04 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Sale62.0740,8002,532,58288,173Oct 04 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Option Exercise33.4939,2001,312,80839,200Sep 01 03:37 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Sale62.6139,2002,454,3080Sep 01 03:37 PM
Golestani ClarkEVP & Chief Info OfficerAug 10Sale63.033,000189,09014,083Aug 10 04:57 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Option Exercise36.85392,00014,446,600900,877Aug 05 05:48 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Sale61.81392,00024,231,096508,877Aug 05 05:48 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 02Option Exercise0.005,150037,570Aug 03 02:51 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Option Exercise51.0227,6211,409,223550,098Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Sale58.0027,6211,602,018522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 05Sale57.9945,0002,609,33087,151Jul 05 12:56 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Option Exercise44.3050,0002,215,00050,000Jul 01 01:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Option Exercise40.7030,0001,221,000162,151Jul 01 01:13 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Option Exercise51.0232,3791,651,977554,856Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Sale58.0032,3791,877,982522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Sale57.4930,0001,724,553132,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Sale57.6950,0002,884,4150Jul 01 01:13 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Option Exercise44.9838,6471,738,34255,730May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Sale54.8038,6472,117,85617,083May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 19Sale54.551,23067,09717,083May 20 02:34 PM
Holston Michael JEVP, General CounselMay 10Option Exercise44.58100,0214,458,989164,301May 12 11:39 AM
Holston Michael JEVP, General CounselMay 10Sale54.50100,0215,451,14564,280May 12 11:39 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 06Option Exercise0.003,335025,928May 09 04:21 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 06Option Exercise0.004,002040,221May 09 04:21 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 06Option Exercise0.002,001015,375May 09 04:21 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLMay 06Option Exercise0.0044,464094,899May 09 04:21 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 06Option Exercise0.004,002033,430May 09 04:20 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise34.445,000172,20016,400Apr 13 03:03 PM